Work

Clinical activity of REM-422, a MYB mRNA degrader, in recurrent/metastatic adenoid cystic carcinoma: Final results from the phase 1/2 dose-escalation cohort.

Year: 2026

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2026.44.16_suppl.6009

Authors: Renata Ferrarotto, Paul Swiecicki, Alan Loh Ho, Alain Patrick Algazi, Meredith McKean, Jennifer Webster, Mythili Koneru, Charles Kung, Glenn J. Hanna

Institutions: The University of Texas MD Anderson Cancer Center, University of Michigan, U-M Rogel Cancer Center, Memorial Sloan Kettering Cancer Center, University of California, San Francisco, Sarah Cannon, Tennessee Oncology, Harvard University, Dana-Farber Cancer Institute

Language: English

Topic: Salivary Gland Tumors Diagnosis and Treatment

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7162553007

Cites:

Cited by: 4

Related to: